| Diffuse Large B-Cell Lymphoma

Adcetris vs Epkinly

Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.

Deep comparison between: Adcetris vs Epkinly with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsEpkinly has a higher rate of injection site reactions vs Adcetris based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Epkinly but not Adcetris, including UnitedHealthcare

Category

Adcetris

Epkinly

At A Glance

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassCD30-directed antibody-drug conjugate

RouteSC injection

FrequencyEvery 1-4 weeks

ClassCD20xCD3 bispecific antibody

Indications

Hodgkin Disease
Angioimmunoblastic Lymphadenopathy
Peripheral T-Cell Lymphoma
Mycosis Fungoides
Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma
High grade B-cell lymphoma
Lymphoma, Follicular

Dosing

Hodgkin Disease (previously untreated Stage III/IV, adults) 1.2 mg/kg (max 120 mg) IV in combination with chemotherapy every 2 weeks for a maximum of 12 doses.

Hodgkin Disease (previously untreated high risk, pediatric) 1.8 mg/kg (max 180 mg) IV in combination with chemotherapy every 3 weeks for a maximum of 5 doses.

Hodgkin Disease (post-auto-HSCT consolidation) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Hodgkin Disease (relapsed) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Peripheral T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy (previously untreated) 1.8 mg/kg (max 180 mg) IV in combination with cyclophosphamide, doxorubicin, and prednisone every 3 weeks for 6 to 8 doses.

Peripheral T-Cell Lymphoma (relapsed systemic ALCL) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Mycosis Fungoides (relapsed pcALCL or CD30-expressing) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.2 mg/kg (max 120 mg) IV in combination with lenalidomide and a rituximab product every 3 weeks until disease progression or unacceptable toxicity.

Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.

Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.

Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.

Contraindications

Concomitant use with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)

—

Drug Interactions

782View drug interactions

694View drug interactions

Adverse Reactions

Most common (>=20%) Peripheral neuropathy, fatigue, nausea, diarrhea, musculoskeletal pain, pyrexia, rash, upper respiratory tract infection, constipation, alopecia

Serious Febrile neutropenia, pneumonia, hepatotoxicity, peripheral motor neuropathy, pulmonary toxicity, progressive multifocal leukoencephalopathy, tumor lysis syndrome, serious and opportunistic infections

Postmarketing Febrile neutropenia, acute pancreatitis, gastrointestinal complications, hepatotoxicity, progressive multifocal leukoencephalopathy, serious and opportunistic infections, hyperglycemia, noninfectious pulmonary toxicity including pneumonitis and ARDS, toxic epidermal necrolysis

Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache

Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS

Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)

Pharmacology

Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of a chimeric IgG1 anti-CD30 antibody linked to MMAE, a microtubule-disrupting agent; upon binding to CD30-expressing tumor cells the ADC is internalized and MMAE is released via proteolytic cleavage, disrupting the microtubule network within the cell and inducing cell cycle arrest and apoptosis.

Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Adcetris